Clinical researchers design a randomized trial comparing a novel topical calcineurin inhib… — USMLE Step 3

Clinical researchers design a randomized trial comparing a novel topical calcineurin inhibitor to standard high-potency topical corticosteroids in patients with severe atopic dermatitis. The primary outcome is achieving a 75% reduction in the Eczema Area and Severity Index (EASI-75) at 12 weeks.

The crude analysis of the entire study cohort shows no statistically significant difference in achieving the primary outcome between the two interventions (Relative Risk [RR] = 1.05, 95% CI: 0.92-1.19).

To investigate further, the research team performs a stratified analysis based on the presence of a null mutation in the filaggrin ( $FLG$ ) gene.

Among subjects harboring the $FLG$ mutation, the RR for achieving EASI-75 with the novel inhibitor versus corticosteroids is 1.65 (95% CI: 1.40-1.95).

Among subjects lacking the $FLG$ mutation, the corresponding RR is 0.85 (95% CI: 0.75-0.96).

Based on these stratified statistical findings, which of the following terms best describes the role of the $FLG$ mutation in this clinical trial?

Effect modifierAnswer
B
Confounding variable
C
Determinant of positive predictive value
D
Categorical dependent variable
E
Source of anchoring bias

Answer

Effect modifier

The correct answer is effect modifier. Effect modification (or interaction) occurs when the magnitude or direction of an exposure's effect on an outcome varies significantly depending on the level of a third variable. In this scenario, the initial crude analysis showed no significant difference between the treatments (RR = 1.05). However, stratification revealed a significant benefit for the novel inhibitor in patients with the mutation (RR = 1.65), and a significant benefit for corticosteroids in patients without the mutation (RR = 0.85). Because the treatment's efficacy fundamentally depends on the patient's genetic status, the

FLG

mutation acts as an effect modifier. This represents a genuine biological interaction rather than an error or distortion in the study design.

Step-by-Step Solution

Evaluate the crude (unstratified) relative risk provided in the study.

The crude RR is 1.05 (95% CI: 0.92-1.19), which is not statistically significant, suggesting no overall difference in efficacy between the two treatments.

Establishing the baseline finding is necessary to understand the impact of subsequent stratification.

Analyze the stratum-specific relative risks after dividing the population by the third variable (

FLG

mutation).

The RR is 1.65 in patients with the mutation (favoring the novel inhibitor) and 0.85 in patients without the mutation (favoring corticosteroids).

Comparing strata identifies how the third variable influences the association between exposure and outcome.

Compare the stratum-specific relative risks to each other and to the crude relative risk.

The stratum-specific RRs are significantly different from each other and point in opposite therapeutic directions, while the crude RR is an average of the two.

This specific statistical pattern—where strata show vastly different effects—is the hallmark of effect modification, differentiating it from confounding.

Key Concept

Effect modification is present when the effect of an exposure on an outcome is altered by the presence of a third variable, indicated by stratum-specific measures of association that are significantly different from one another.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic